(MedPage Today) — A compounded form of imiquimod, a topical immune response-modifying therapy approved for basal cell carcinoma and other conditions, showed promise as a treatment for ocular surface malignancies in a small case series.
In five…
Source link : https://www.medpagetoday.com/ophthalmology/generalophthalmology/118764
Author :
Publish date : 2025-12-01 18:39:00
Copyright for syndicated content belongs to the linked Source.
